|
|
Volumn 303, Issue 14, 2010, Pages 1355-1356
|
|
New oversight put in place for physicians giving anemia drugs to patients with cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
ZIDOVUDINE;
ANTINEOPLASTIC AGENT;
DRUG DERIVATIVE;
ERYTHROPOIETIN;
ANEMIA;
BREAST CANCER;
BREAST METASTASIS;
CANCER PATIENT;
CANCER THERAPY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG FATALITY;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MEGADOSE;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HEAD AND NECK CANCER;
HEALTH CARE COST;
HEALTH CARE PERSONNEL;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
KIDNEY FAILURE;
MEDICAL DOCUMENTATION;
MEDICAL SOCIETY;
NEOPLASM;
PHYSICIAN;
PRESCRIPTION;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RISK MANAGEMENT;
SHORT SURVEY;
SURVIVAL TIME;
TUMOR GROWTH;
DOCUMENTATION;
HEALTH CARE POLICY;
NOTE;
UNITED STATES;
ANEMIA;
ANTINEOPLASTIC AGENTS;
DOCUMENTATION;
EPOETIN ALFA;
ERYTHROPOIETIN;
HEALTH POLICY;
HEMATINICS;
HUMANS;
NEOPLASMS;
RISK MANAGEMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 77950892750
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2010.359 Document Type: Short Survey |
|
Times cited : (7)
|
|
References (0)
|
